December 8, 2020
TIAP announces co-funding of transformative projects with Amgen to support new venture development
Toronto Innovation Acceleration Partners (TIAP) is excited to announce co-investments made with a key strategic partner, Amgen Inc., into three translational life sciences projects from its members: University of Toronto, University Health Network (UHN) and The Hospital for Sick Children (SickKids).
The TIAP-Amgen partnership, formalized in 2019, has an objective to jointly fund nascent technologies managed by TIAP on behalf of its Toronto-based member institutions. The two organizations ...
Agreement signed as part of Ontario's life sciences trade mission to Israel
TEL AVIV and TORONTO (May 16, 2016) – BioLineRx Ltd. a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has signed a framework collaboration agreement with MaRS Innovation, the commercialization agent for 15 of Toronto's top academic institutions.
Under the terms of the agreement, BioLineRx intends to review innovative projects and assets of start-up companies originating from MaRS Innovation's members to identify in-licensing, co-development or other ...
TORONTO (May 11, 2016) – Johnson & Johnson Innovation LLC, today announced the opening of JLABS @ Toronto, a new 40,000-square-foot life sciences incubator, providing entrepreneurs shared lab space and offices, modular lab suites and access to scientific, industry and capital funding experts as they work to build important and successful early-stage companies. The new JLABS facility can accommodate up to 50 start-ups and opens with 22 companies that represent a range of sectors including therapeutics, medical devices and consumer health ...
May 11, 2016
in Baycrest Centre for Geriatric Care, Centre for Addiction and Mental Health (CAMH), Government Partners, Holland Bloorview Kids Rehabilitation Hospital, Industry Partners, MaRS Discovery District, Media Coverage, Member Institutions, News, Partnerships, Ryerson University, Sinai Health, St. Michael's Hospital, Sunnybrook Health Sciences Centre, The Hospital for Sick Children (SickKids), The Ontario Institute for Cancer Research (OICR), Thunder Bay Regional Research Institute (TBRRI), University Health Network, University of Toronto, Women's College Hospital, York University
Companies in fourth cohort developing products ranging from software to therapeutic platforms; applications for fifth cohort, in partnership with MLA48, open until May 27, 2016
TORONTO (May 9, 2016) — The University of Toronto Early-Stage Technology (UTEST) incubator, co-directed by U of T’s Innovations & Partnerships Office (IPO) and MaRS Innovation with financial support from the Connaught Fund, has announced five investments in start-up companies from Cohort 4.
The five companies and the diverse sectors they target are:
Ardra Bio, which is ...
Canadian biotech company developing ground-breaking therapeutic designed to minimize dermal scarring (fibrosis)
TORONTO (February 16, 2016) — ScarX Therapeutics, a Canadian biotechnology company commercializing innovative treatments for dermal scarring (fibrosis), has closed a $2 million Series A financing. The company will complete a Phase I clinical trial of its lead candidate, SCX-001, in human volunteers, with the eventual goal of creating better functional and cosmetic patient outcomes.
This announcement was covered in TechVibes, BetaKit, Biotechnology Focus, PEHub, Finsmes, and StartupHere Toronto.
SCX-001 is the ...
TORONTO and SAN DIEGO (December 8, 2015) — Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept, today announced that positive results from its ongoing Phase 1 proof-of-concept study evaluating marizomib in patients with relapsed and refractory multiple myeloma will be presented at the 57th Annual Meeting of the American Society of Hematology (ASH).
The company will also present preclinical data on marizomib demonstrating synergistic activity in combination with pomalidomide. Marizomib is a novel ...
TORONTO and SAN DIEGO (November 19, 2015) -- Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for marizomib to treat patients with malignant glioma.
Malignant glioma is an aggressive form of brain cancer for which there is a significant unmet need in current treatments due to the disease's poor prognosis. Triphase is evaluating marizomib, a novel and highly ...
Prima IP co-sponsoring the Ryerson University and St. Michael’s Hospital event
When your business demands staying current with the newest inventions springing up across 15 academic members, keeping pace with what’s happening is half the challenge.
That’s part of the reason why MaRS Innovation and Prima IP are sponsoring winners of an Angels’ Den competition involving the Institute for Biomedical Engineering, Science and Technology (iBEST).
iBEST is a partnership between Ryerson University and St. Michael's Hospital that brings together Ryerson's engineering and science strengths ...
MaRS Innovation's "model solves the two weakest points in tech transfer: the lack of dealflow and the ability to match public funding," writes Thierry Heles in, "MaRS Innovation: A Unique Model for Tech Transfer," for Global University Venturing.
This feature was also covered in Techopia.
The article, which includes an interview with Dr. Rafi Hofstein, president and CEO of MaRS Innovation, was published September 14, 2015.
Here's an excerpt exploring the range of MI's portfolio and Hofstein's strategy for addressing technologies emerging in new ...
CQDM and MaRS Innovation investing in new Encycle project to determine rules for making peptide drugs orally bioavailable
PHILADELPHIA (June 16, 2015) — FiercePharma has predicted that the pharmaceutical industry stands to lose $44 billion in drugs going off patent in 2015. The industry is searching for new therapeutics to replenish their pipelines while tackling existing and new drug receptor targets within the cell, improve patient care and lower administrative costs. In this context, drugs that can be orally swallowed, known as ...
June 16, 2015
in Encycle Therapeutics, Funding or Fundraising-Announcements, Government Partners, Industry Partners, Member Institutions, News, Partnerships, Portfolio, Start-Up Companies, University of Toronto